Zamaglutenase is a recombinant enzyme commercialized by Takeda Pharmaceutical, with a leading Phase II program in Celiac Disease. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zamaglutenase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Zamaglutenase is expected to reach an annual total of $1 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zamaglutenase Overview
Kuma-062 is under development for the treatment of celiac disease. The therapeutic candidate is administered through oral route as a capsule, tablet and liquid. KumaMax is an enzyme that acts by targeting alpha-gliadin (the immunoreactive part of gluten). Kuma-062 is a Kuma-010 variant. It is a new molecular entity.
Takeda Pharmaceutical Overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY4,027,478 million for the fiscal year ended March 2023 (FY2023), an increase of 12.8% over FY2022. In FY2023, the company’s operating margin was 12.2%, compared to an operating margin of 12.5% in FY2022. In FY2023, the company recorded a net margin of 7.9%, compared to a net margin of 6.4% in FY2022.
For a complete picture of Zamaglutenase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
